Why the study?
Does Tinzaparin have a different effect on platelet aggregation compared to unfractionated heparin in vitro and ex vivo?
Does Tinzaparin have a different effect on platelet aggregation compared to unfractionated heparin in vitro and ex vivo?
Tinzaparin demonstrates a less proaggregatory effect on platelets than unfractionated heparin, suggesting a potentially favorable platelet activation profile.
Answers are grounded in this paper and cite their sources.
Animal data on differential platelet effects should not change heparin selection; hypothesis-generating for human relevance.
A low-molecular-weight heparin (LMWH), when anti-IIa activity was compared. In the ex vivo part Tinzaparin, was compared with unfractionated heparin of the study, a significant enhancement of ADP-induced (UFH) for their effects on platelet aggregation in vitro and platelet aggregation was observed after i.v. administra ex vivo. Both heparins showed a dose-dependent proag- tion of both Tinzaparin and UFH with no difference in gregatory effect on ADP- and collagen-induced platelet potency. Subcutaneous administration of Tinzaparin in aggregation in vitro, but LMWH was less potent. The two different doses did not have any effect on platelet differences in potency between Tinzaparin and UFH de- activity. In conclusion, Tinzaparin appears, like other pended on how the compounds were compared. The most LMWHs, to have less proaggregatory effect on platelets pronounced difference was found when molar concentra- than UFH both in vitro and ex vivo.
No takes yet. Share an insight, caveat, or question.
Ravn et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: